Adjustable intraocular lens technology for post-cataract surgery vision correction
RxSight manufactures adjustable intraocular lenses (IOLs) that can be customized after cataract surgery, addressing a key limitation of traditional fixed-power implants. The company is sales-driven (30 of 72 active roles) with aggressive hiring velocity, reflecting a push to expand clinical adoption and same-store growth — both listed as top pain points. Projects center on adoption strategy, clinical training, and customer onboarding, signaling internal focus on converting equipped practices into consistent users of the platform.
Notable leadership hires: Sales Director, Director of Sales
RxSight is a publicly traded ophthalmic medical device company headquartered in Aliso Viejo, California, and founded in 1997. The core product is the world's first and only adjustable IOL, which allows surgeons to refine patients' vision after cataract surgery rather than relying on pre-operative calculations alone. The company sells into cataract surgery practices and serves patients across ophthalmology clinics. Operations span manufacturing, clinical training, and sales infrastructure across the U.S. and key Asia-Pacific markets (Japan, South Korea, Taiwan, Australia, Malaysia, China, Philippines) and Germany.
The RxSight IOL is implanted during cataract surgery and allows surgeons to adjust the lens power after surgery to optimize vision for each patient's eye, correcting presbyopia and refractive error without requiring a second surgery.
RxSight is headquartered in Aliso Viejo, California, and employs 201–500 people. It operates globally with hiring across the U.S., Germany, Philippines, Malaysia, China, Japan, South Korea, Taiwan, and Australia.
Other companies in the same industry, closest in size